[(2-茚满甲酰基)甲基]膦酸二甲酯 | 53273-26-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 中文名称: [(2-茚满甲酰基)甲基]膦酸二甲酯
• 英文名称: dimethyl <(2-indanoyl)methyl>phosphonate
• 英文别名: dimethyl 2-oxo-2-(2-indanyl)ethylphosphonate；<2-(2-Indanyl)-2-oxo>-aethylphosphonsaeure-dimethylester；(2-indan-2-yl-2-oxoethyl)phosphonic acid dimethyl ester；2-Dimethoxyphosphoryl-1-indan-2-yl-ethanone；1-(2,3-dihydro-1H-inden-2-yl)-2-dimethoxyphosphorylethanone
• CAS: 53273-26-0
• 化学式: C₁₃H₁₇O₄P
• 分子量: 268.249
• InChiKey: INDCQOTULGRLGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2931900090

反应信息

• 作为反应物：
  描述：

  [(2-茚满甲酰基)甲基]膦酸二甲酯 在 N-氯代丁二酰亚胺 、 sodium hydride 作用下， 生成 chloro(2-indanoyl)methyl dimethylphosphonate
  参考文献：
  名称：

  Synthesis and biological activity of novel carbacyclins having bicyclic substituents on the .omega.-chain

  摘要：

  A number of carbacyclins having bicyclic substituents on the omega-chain have been synthesized and tested for antiplatelet aggregation activity in vitro (against collagen-induced aggregation of rat platelet), for reduction of systemic blood pressure in vivo (ability to reduce the blood pressure in anesthetized rat by iv injection), and for cytoprotective activity (protection against ethanol-induced rat gastric lesion). The most effective compound for each activity was [3aS-[2E,3a alpha,4 alpha (3R),5 beta,6a alpha]]-5-[hexahydro-5- hydroxy-4-[3-hydroxy-3-(2-indanyl)-1-propynyl]-2(1H)-pentalenylidene+ ++] pentanoic acid (compound 11a), while some 1,4-benzodioxan analogues had selectivity for organ-protective activity, and indan analogues showed selectivity in their antiaggregation activity.

  DOI：

  10.1021/jm00128a049
• 作为产物：
  描述：

  2-茚羧酸 在 正丁基锂 、 硫酸 作用下， 反应 3.0h， 生成 [(2-茚满甲酰基)甲基]膦酸二甲酯
  参考文献：
  名称：

  Synthesis and biological activity of novel carbacyclins having bicyclic substituents on the .omega.-chain

  摘要：

  A number of carbacyclins having bicyclic substituents on the omega-chain have been synthesized and tested for antiplatelet aggregation activity in vitro (against collagen-induced aggregation of rat platelet), for reduction of systemic blood pressure in vivo (ability to reduce the blood pressure in anesthetized rat by iv injection), and for cytoprotective activity (protection against ethanol-induced rat gastric lesion). The most effective compound for each activity was [3aS-[2E,3a alpha,4 alpha (3R),5 beta,6a alpha]]-5-[hexahydro-5- hydroxy-4-[3-hydroxy-3-(2-indanyl)-1-propynyl]-2(1H)-pentalenylidene+ ++] pentanoic acid (compound 11a), while some 1,4-benzodioxan analogues had selectivity for organ-protective activity, and indan analogues showed selectivity in their antiaggregation activity.

  DOI：

  10.1021/jm00128a049

文献信息

• A General Procedure for the Preparation of β-Ketophosphonates
  作者：Kevin M. Maloney、John Y. L. Chung

  DOI：10.1021/jo901552k

  日期：2009.10.2

  A mild, high-yielding procedure for the preparation of β-ketophosphonates is described. The condensation is general with respect to the ester and phosphonate, and the products are obtained in high yields within minutes at 0 °C. The reaction procedure is operationally simple and amenable to large-scale preparations.

  描述了制备β-酮膦酸酯的温和的高产率方法。对于酯和膦酸酯而言，缩合是普遍的，并且在0℃下在数分钟内以高收率获得产物。该反应程序操作简单并且适于大规模制备。
• 15-Substituted-.omega.-pentanorprostaglandins
  申请人：Pfizer Inc.

  公开号：US04152527A1

  公开（公告）日：1979-05-01

  The 15-substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.

  这项发明中使用的15-取代-ω-戊烷基前列腺素及其制备中使用的各种中间体。这种新型前列腺素被发现具有与母体前列腺素相当的活性特征，但表现出更强的组织特异性作用。
• 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
  申请人：Alcon Laboratories, Inc.

  公开号：US06353000B1

  公开（公告）日：2002-03-05

  A method of treating glaucoma or ocular hypertension in a patient, which comprises administering to the patient a pharmaceutically effective amount of a compound of formula I:

  一种治疗青光眼或眼压增高的方法，包括向患者施用公式I的化合物的药物有效量。
• 11Beta-fluoro 15beta-hydroxy PGF2alpha analogs as FP receptor antagonists
  申请人：——

  公开号：US20030083375A1

  公开（公告）日：2003-05-01

  Methods and compositions for the antagonism of FP receptor-mediated biological responses are disclosed.

  本发明揭示了用于拮抗FP受体介导的生物反应的方法和组合物。
• PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS
  申请人：Barta Nancy S.

  公开号：US20090221654A1

  公开（公告）日：2009-09-03

  A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.

  一种具有对EP受体选择性的前列腺素类似物，表现出EP激动剂活性，可用于扩大造血干细胞群体或治疗或预防流感、骨折、骨病、青光眼、眼压增高、痛经、早产、免疫障碍、骨质疏松症、哮喘、过敏、男性性功能障碍、女性性功能障碍、牙周病、胃溃疡、肾脏疾病或其他EP受体介导的疾病。